Dow Jones
39.118,86 -45,24 (-0,12%) Nasdaq
17.732,60 -126,10 (-0,71%) Nikkei 225
39.583,08 +241,58 (+0,61%) EUR/USD
1,0739 +0,0030 (+0,28%) Bitcoin EUR
58.474,29 +1.780,72 (+3,14%) CMC Crypto 200
1.290,17 +6,34 (+0,49%)
Merus N.V. (MRUS)
Dopo ore:
| Chiusura precedente | 60,20 |
| Aperto | 59,95 |
| Denaro | 58,93 x 300 |
| Domanda | 59,20 x 400 |
| Min-Max giorno | 58,31 - 61,28 |
| Intervallo di 52 settimane | 19,81 - 61,61 |
| Volume | |
| Media Volume | 1.001.571 |
| Capitalizzazione | 3,986B |
| Beta (mensile su 5 anni) | 1,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,73 |
| Prossima data utili | 05 ago 2024 - 09 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 87,42 |
GlobeNewswireMerus Announces Business Update Conference Call
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported by INTERLINK-1 control armClinical data update on petosemtamab monotherapy in 2L+ HNSCC planned 2024MCLA-129 abstracts accepted at ESMO AsiaInvestor call on Monday, October 16 at 7:30 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.
- GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acc
- GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ETMorgan Stanley 21st A
